JP2018509438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509438A5 JP2018509438A5 JP2017549483A JP2017549483A JP2018509438A5 JP 2018509438 A5 JP2018509438 A5 JP 2018509438A5 JP 2017549483 A JP2017549483 A JP 2017549483A JP 2017549483 A JP2017549483 A JP 2017549483A JP 2018509438 A5 JP2018509438 A5 JP 2018509438A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- replaced
- pharmaceutical composition
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 63
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 239000003862 glucocorticoid Substances 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 102000008122 Casein Kinase I Human genes 0.000 claims 2
- 108010049812 Casein Kinase I Proteins 0.000 claims 2
- 241000709661 Enterovirus Species 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 239000013566 allergen Substances 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 229920002494 Zein Polymers 0.000 claims 1
- 108010055615 Zein Proteins 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- -1 hydrate Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 208000020017 viral respiratory tract infection Diseases 0.000 claims 1
- 239000005019 zein Substances 0.000 claims 1
- 229940093612 zein Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015901032A AU2015901032A0 (en) | 2015-03-23 | Treatment of respiratory diseases | |
| AU2015901032 | 2015-03-23 | ||
| PCT/AU2016/050209 WO2016149756A1 (en) | 2015-03-23 | 2016-03-23 | Treatment of respiratory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021007384A Division JP7169693B2 (ja) | 2015-03-23 | 2021-01-20 | 呼吸器疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509438A JP2018509438A (ja) | 2018-04-05 |
| JP2018509438A5 true JP2018509438A5 (https=) | 2019-05-09 |
| JP6827948B2 JP6827948B2 (ja) | 2021-02-10 |
Family
ID=56976881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549483A Active JP6827948B2 (ja) | 2015-03-23 | 2016-03-23 | 呼吸器疾患の治療 |
| JP2021007384A Active JP7169693B2 (ja) | 2015-03-23 | 2021-01-20 | 呼吸器疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021007384A Active JP7169693B2 (ja) | 2015-03-23 | 2021-01-20 | 呼吸器疾患の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10722513B2 (https=) |
| EP (2) | EP4591936A3 (https=) |
| JP (2) | JP6827948B2 (https=) |
| CN (3) | CN107847480B (https=) |
| ES (1) | ES3055494T3 (https=) |
| FI (1) | FI3273955T3 (https=) |
| PT (1) | PT3273955T (https=) |
| WO (1) | WO2016149756A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847480B (zh) | 2015-03-23 | 2021-06-25 | 墨尔本大学 | 呼吸性疾病的治疗 |
| JP2016193861A (ja) * | 2015-03-31 | 2016-11-17 | 国立大学法人山梨大学 | マスト細胞活性化を抑制するための医薬組成物 |
| TW201837027A (zh) * | 2017-02-01 | 2018-10-16 | 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 | 吡唑衍生物及其用途 |
| PT3619204T (pt) * | 2017-05-03 | 2025-10-29 | Tianli Biotech Pty Ltd | Compostos para o tratamento de doenças respiratórias |
| WO2019090405A1 (pt) * | 2017-11-11 | 2019-05-16 | Carvalho Junior Mario Virgilio De | Medicamento de ciclesonida para cura e prevenção da gripe causada pelo vírus influenza |
| JP7575099B2 (ja) * | 2018-11-07 | 2024-10-29 | ティアンリ バイオテック プロプライエタリ リミテッド | 呼吸器疾患の処理のための新規な化合物 |
| KR102253324B1 (ko) * | 2019-11-27 | 2021-05-18 | 단디바이오사이언스 주식회사 | 호흡기 질환의 예방, 개선 또는 치료용 조성물 |
| US11801304B2 (en) * | 2020-02-19 | 2023-10-31 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof |
| AR122711A1 (es) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| IL305165A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| US12600721B2 (en) | 2021-02-19 | 2026-04-14 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| CA3207819A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| WO2022235621A1 (en) * | 2021-05-03 | 2022-11-10 | Thirona Bio, Inc. | Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor |
| CN115792229B (zh) * | 2022-01-28 | 2024-06-18 | 华中科技大学同济医学院附属同济医院 | 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用 |
| WO2024091485A1 (en) * | 2022-10-25 | 2024-05-02 | The Regents Of The University Of California | Compositions and methods for treating or preventing pulmonary fibrosis |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| IL110296A (en) | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| US5593991A (en) | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| FI972970A7 (fi) * | 1995-01-12 | 1997-09-11 | Smithkline Beecham Corp | Uusia yhdisteitä |
| US6369068B1 (en) | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| JP2000507558A (ja) | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Ｃｎｓ損傷についての新規な治療 |
| TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
| WO1999032121A1 (en) | 1997-12-19 | 1999-07-01 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
| US6598603B1 (en) | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| EP1257546A1 (en) * | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| WO2004028545A1 (en) | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| CN1968716A (zh) * | 2003-01-09 | 2007-05-23 | 阿里泽克药品公司 | 治疗肺疾病的方法 |
| GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| EP1713473B1 (en) | 2004-02-06 | 2013-03-13 | MEDA Pharma GmbH & Co. KG | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| WO2005103240A1 (en) * | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 1 (csnk1d iso 1) |
| CN101031568A (zh) * | 2004-06-23 | 2007-09-05 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| JP2009514876A (ja) * | 2005-11-03 | 2009-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼのための化合物および組成物 |
| WO2008094208A2 (en) | 2006-08-02 | 2008-08-07 | Northwestern University | Protein kinase targeted therapeutics |
| WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| AU2008211613B2 (en) * | 2007-02-02 | 2013-05-23 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| US20090136427A1 (en) * | 2007-09-18 | 2009-05-28 | La Jolla Institute For Allergy And Immunology | LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| EP2317849A4 (en) * | 2008-06-26 | 2011-11-02 | Inspire Pharmaceuticals Inc | PROCESS FOR THE TREATMENT OF LUNG DISEASES WITH RHO KINASE INHIBITOR COMPOUNDS |
| EP2344126A1 (en) | 2008-10-14 | 2011-07-20 | Activaero GmbH | Method for treatment of copd and other pulmonary diseases |
| FR2943058B1 (fr) * | 2009-03-11 | 2011-06-03 | Centre Nat Rech Scient | Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique. |
| SI2493876T1 (sl) * | 2009-10-28 | 2014-04-30 | Pfizer Inc. | Derivati imidazola kot inhibitorji kazein-kinaze |
| US20120263715A1 (en) * | 2009-10-28 | 2012-10-18 | Medimmune, Llc | Topical Methods Of Treating RSV Infections And Related Conditions |
| US9801853B2 (en) * | 2010-04-06 | 2017-10-31 | Fred Hutchinson Cancer Research Center | Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells |
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| EP2589385A1 (en) * | 2011-11-03 | 2013-05-08 | Fundación Centro Nacional de Investigaciones Oncológicas | Triple combination for the treatment of cancer |
| WO2014018691A1 (en) * | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres |
| CZ2012538A3 (cs) | 2012-08-08 | 2014-02-19 | Masarykova Univerzita | Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie |
| JP5990862B2 (ja) | 2012-10-01 | 2016-09-14 | 国立研究開発法人科学技術振興機構 | 承認予測装置、承認予測方法、および、プログラム |
| CN103784451A (zh) * | 2012-10-31 | 2014-05-14 | 无锡蕾明视康科技有限公司 | 一种治疗抑郁症的药物 |
| EP2935272B1 (en) * | 2012-12-21 | 2017-02-22 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| JP6267231B2 (ja) | 2012-12-21 | 2018-01-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール |
| CA2937992A1 (en) | 2014-02-03 | 2015-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of eliminating stem cells |
| CN107847480B (zh) | 2015-03-23 | 2021-06-25 | 墨尔本大学 | 呼吸性疾病的治疗 |
| JP2016193861A (ja) | 2015-03-31 | 2016-11-17 | 国立大学法人山梨大学 | マスト細胞活性化を抑制するための医薬組成物 |
| WO2017083971A1 (en) | 2015-11-16 | 2017-05-26 | University Of Manitoba | Compositions and methods for treatment of influenza |
| EP3531830A4 (en) | 2016-10-28 | 2020-08-26 | University of Utah Research Foundation | METHODS AND COMPOSITIONS FOR IDENTIFICATION AND TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER |
| PT3619204T (pt) | 2017-05-03 | 2025-10-29 | Tianli Biotech Pty Ltd | Compostos para o tratamento de doenças respiratórias |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| MX2021002652A (es) | 2018-09-09 | 2021-09-23 | Qanatpharma Ag | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. |
-
2016
- 2016-03-23 CN CN201680026219.6A patent/CN107847480B/zh active Active
- 2016-03-23 CN CN202110650935.4A patent/CN113350353A/zh active Pending
- 2016-03-23 WO PCT/AU2016/050209 patent/WO2016149756A1/en not_active Ceased
- 2016-03-23 PT PT167675339T patent/PT3273955T/pt unknown
- 2016-03-23 CN CN202110636730.0A patent/CN113350352B/zh active Active
- 2016-03-23 FI FIEP16767533.9T patent/FI3273955T3/fi active
- 2016-03-23 JP JP2017549483A patent/JP6827948B2/ja active Active
- 2016-03-23 US US15/559,360 patent/US10722513B2/en active Active
- 2016-03-23 EP EP25174466.0A patent/EP4591936A3/en active Pending
- 2016-03-23 EP EP16767533.9A patent/EP3273955B1/en active Active
- 2016-03-23 ES ES16767533T patent/ES3055494T3/es active Active
-
2020
- 2020-06-30 US US16/917,581 patent/US11564925B2/en active Active
-
2021
- 2021-01-20 JP JP2021007384A patent/JP7169693B2/ja active Active
-
2022
- 2022-12-22 US US18/087,672 patent/US11975005B2/en active Active
-
2024
- 2024-04-04 US US18/627,415 patent/US20240245690A1/en active Pending